Results 71 to 80 of about 21,829 (156)

Guidelines for Essential Trauma Care: Second Edition (2026)

World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock, Timothy C. Hardcastle, Christine Gaarder, Amit Gupta, Adam Gyedu, Manjul Joshipura, Elmin Steyn, on behalf of the Essential Trauma Care revision author group, Valencia Adjei, Roger Alcock, Vanda Amado, Michael Boampong, Sanjeev Booi, Petra Brysiewicz, Corazon Cabanilla‐Manuntag, Cristiane de Alencar Domingues, Ghada Elhadari, Ranjith Nanda Ellawala, Sarnai Erdene, Ama Akoma Essuman, Jorge Esteban Foianini, Filippo Gatti, Armando Garcia Guererra, Greg Hynes, Adil Haider, Sandy Ingless, Balavenkata Jagannathan, Helen Jowett, Knut Magne Kolstadbråten, Sonja Krofak, Aireen Patricia Madrid, Tina Tomić Mahečić, Claude Martin, Daniel Ntogwrachu, Bisola Onajin‐Obembe, Nhobojit Roy, Andres Rubiano, Niisoja Mensah Torto, Ben Wachira, Meg Walmsley, Torben Wisborg, Elma Wong   +41 more
wiley   +1 more source

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against multidrug-resistant Klebsiella pneumoniae and Escherichia coli

, 2019
Background: Increasing resistance to broad-spectrum cephalosporin and carbapenem in Enterobacteriaceae makes it challenging to select appropriate antibiotics. There are limited treatment options for these pathogens.
이승철
core   +1 more source

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient

IDCases, 2019
Ceftazidime–avibactam is a combination agent consisting of the β-lactamase inhibitor avibactam and the broad-spectrum cephalosporin ceftazidime. There are no published case reports or studies evaluating the use of CAZ-AVI in pediatric critically ill ...
Maria Vargas, Antonio Riccardo Buonomo, Pasquale Buonanno, Carmine Iacovazzo, Giuseppe Servillo   +4 more
doaj   +1 more source

Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive Klebsiella pneumoniae MBL+, NDM+ [PDF]

Mateusz Szymański,1,2 Małgorzata M Skiba,2 Małgorzata Piasecka,2 Alina Olender3 1Human Anatomy Department, Medical University, Lublin, Poland; 2Intensive Care Unit, Stefan Cardinal Wyszyński District Specialist Hospital ...
Szymański M, Olender A, Skiba MM, Piasecka M   +3 more
core  

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration

, 2017
Ceftazidime-avibactam administered at 1.25 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa bacteremia in a critically ill patient on continuous venovenous hemofiltration (CVVH).
Eric Wenzler, Larry H. Danziger, Scott Benken, Susan C. Bleasdale, Kristen L. Bunnell, Keith A. Rodvold   +5 more
core   +1 more source

Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2 [PDF]

, 2017
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abscess
Pop-Damkov, P., Petar Pop-Damkov, Taryn Sleger, Slee, A.M., Laud, P.J., Sleger, T., Kevin M. Krause, Krause, K.M., Nichols, W.W., Andrew M. Slee, Gangl, E., Peter J. Laud, Eric Gangl, Wright W. Nichols   +13 more
core   +1 more source

In Vitro Efficacy of Ceftazidime-avibactam Against blaOXA-48 Carrying Klebsiella pneumoniae Isolates

, 2023
Introduction: The healthcare burden of carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) infections is growing. The newly developed beta-lactam/beta-lactamase inhibitor combination, ceftazidime-avibactam, shows promise in the treatment of such ...
Haluk Vahaboğlu, Demet HACISEYİTOĞLU, Rıza Aytaç Cetinkaya, Mücahide Esra Kocoglu, Yasemin Cag, Hülya Çaskurlu, Demet Hacıseyitoglu, Aylin Üsküdar Güclü, Hasan Cenk Mirza   +8 more
core   +1 more source

Review of ceftazidime-avibactam for the treatment of infections caused by pseudomonas aeruginosa

, 2021
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
da Cunha, C.A., Irani, P., Baillon-Plot, N., Tawadrous, M., Daikos, G.L., Rossolini, G.M., Stone, G.G.   +6 more
core   +1 more source

In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae

Antimicrobial Resistance and Infection Control, 2018
Background In recent years, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections has increased rapidly. Since the CRE strain is usually resistant to most of antimicrobial agents, patients with this infection are often accompanied by ...
Wenxia Zhang, Yan Guo, Jiayin Li, Yiyuan Zhang, Yang Yang, Dong Dong, Demei Zhu, Ping He, Fupin Hu   +8 more
doaj   +1 more source

Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance [PDF]

Enterobacterales with carbapenemase-independent resistance to carbapenems are sometimes selected during therapy and, on rare occasions, cause outbreaks. Most have extended-spectrum or AmpC β-lactamases, together with changes to permeability or penicillin-
Vickers, Anna, Livermore, David M., Woodford, Neil, Mushtaq, Shazad   +3 more
core   +1 more source